<?xml version='1.0' encoding='utf-8'?>
<document id="29427135"><sentence text="Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model."><entity charOffset="27-37" id="DDI-PubMed.29427135.s1.e0" text="amlodipine" /><entity charOffset="67-76" id="DDI-PubMed.29427135.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.29427135.s1.e0" e2="DDI-PubMed.29427135.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s1.e0" e2="DDI-PubMed.29427135.s1.e1" /></sentence><sentence text="Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors"><entity charOffset="0-10" id="DDI-PubMed.29427135.s2.e0" text="Amlodipine" /></sentence><sentence text=" Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatment regimens"><entity charOffset="1-10" id="DDI-PubMed.29427135.s3.e0" text="Ritonavir" /><entity charOffset="12-15" id="DDI-PubMed.29427135.s3.e1" text="RTV" /><pair ddi="false" e1="DDI-PubMed.29427135.s3.e0" e2="DDI-PubMed.29427135.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s3.e0" e2="DDI-PubMed.29427135.s3.e1" /></sentence><sentence text=" Drug-drug interaction (DDI) between RTV and amlodipine is due to mixed inhibition and induction of CYP3A4, which is challenging to predict without a mechanistic model that accounts for the complexity of both mechanisms occurring simultaneously"><entity charOffset="45-55" id="DDI-PubMed.29427135.s4.e0" text="amlodipine" /><entity charOffset="37-46" id="DDI-PubMed.29427135.s4.e1" text="RTV" /><pair ddi="false" e1="DDI-PubMed.29427135.s4.e1" e2="DDI-PubMed.29427135.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29427135.s4.e1" e2="DDI-PubMed.29427135.s4.e0" /></sentence><sentence text=" A novel physiologically-based pharmacokinetic (PBPK) model was developed for amlodipine, and the model was verified using published clinical PK and DDI data"><entity charOffset="78-88" id="DDI-PubMed.29427135.s5.e0" text="amlodipine" /></sentence><sentence text=" The verified amlodipine PBPK model was linked to a pharmacodynamics model that describes changes in systolic blood pressure (SBP) during and after co-administration with RTV"><entity charOffset="14-24" id="DDI-PubMed.29427135.s6.e0" text="amlodipine" /><entity charOffset="171-180" id="DDI-PubMed.29427135.s6.e1" text="RTV" /><pair ddi="false" e1="DDI-PubMed.29427135.s6.e0" e2="DDI-PubMed.29427135.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s6.e0" e2="DDI-PubMed.29427135.s6.e1" /></sentence><sentence text=" The magnitude and time course of RTV effects on amlodipine plasma exposures and SBP were evaluated, to provide guidance on dose adjustment of amlodipine during and after co-administration with RTV-containing regimens"><entity charOffset="49-59" id="DDI-PubMed.29427135.s7.e0" text="amlodipine" /><entity charOffset="143-153" id="DDI-PubMed.29427135.s7.e1" text="amlodipine" /><entity charOffset="34-43" id="DDI-PubMed.29427135.s7.e2" text="RTV" /><entity charOffset="194-203" id="DDI-PubMed.29427135.s7.e3" text="RTV" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e2" e2="DDI-PubMed.29427135.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e2" e2="DDI-PubMed.29427135.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e2" e2="DDI-PubMed.29427135.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e2" e2="DDI-PubMed.29427135.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e0" e2="DDI-PubMed.29427135.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e0" e2="DDI-PubMed.29427135.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e0" e2="DDI-PubMed.29427135.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e1" e2="DDI-PubMed.29427135.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29427135.s7.e1" e2="DDI-PubMed.29427135.s7.e3" /></sentence><sentence text=" Model simulations suggested that the increase in amlodipine's plasma exposure by RTV diminishes by approximately 80% within 5 days after the last dose of RTV"><entity charOffset="82-84" id="DDI-PubMed.29427135.s8.e0" text="RTV" /><entity charOffset="155-157" id="DDI-PubMed.29427135.s8.e1" text="RTV" /><pair ddi="false" e1="DDI-PubMed.29427135.s8.e0" e2="DDI-PubMed.29427135.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s8.e0" e2="DDI-PubMed.29427135.s8.e1" /></sentence><sentence text=" PBPK simulations suggested that resuming a full dose of amlodipine [5 mg once daily (QD)] immediately after RTV's last dose would decrease daily average SBP by a maximum of 3"><entity charOffset="57-67" id="DDI-PubMed.29427135.s9.e0" text="amlodipine" /><entity charOffset="109-118" id="DDI-PubMed.29427135.s9.e1" text="RTV" /><pair ddi="false" e1="DDI-PubMed.29427135.s9.e0" e2="DDI-PubMed.29427135.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29427135.s9.e0" e2="DDI-PubMed.29427135.s9.e1" /></sentence><sentence text="3 mmHg, while continuing with the reduced dose (2" /><sentence text="5 mg QD) for 5 days after the last dose of RTV would increase daily average SBP by a maximum of 5"><entity charOffset="43-45" id="DDI-PubMed.29427135.s11.e0" text="RTV" /></sentence><sentence text="8 mmHg" /><sentence text=" Based on these results, either approach of resuming amlodipine's full dose could be appropriate when combined with appropriate clinical monitoring" /><sentence text="" /></document>